Holen Sie sich die Stockscreener-App
30.42
0.23%
0.1128
Schlusskurs vom Vortag:
$30.31
Offen:
$30.37
24-Stunden-Volumen:
122.92K
Relative Volume:
0.06
Marktkapitalisierung:
$19.51B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
20.28
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+4.08%
1M Leistung:
-4.50%
6M Leistung:
+52.43%
1J Leistung:
+35.20%
1-Tages-Spanne:
$30.26
$30.48
1-Wochen-Bereich:
$28.15
$30.44
52-Wochen-Spanne:
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
30.41 | 17.89B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.43 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.53 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.79 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
896.81 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
195.45 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Genmab A/S - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
FY2025 EPS Estimates for Genmab A/S Raised by William Blair - Defense World
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd - Defense World
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London - GlobeNewswire Inc.
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - MSN
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
William Blair Predicts Genmab A/S FY2027 Earnings - Defense World
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs - Defense World
GMAB or TECH: Which Is the Better Value Stock Right Now? - MSN
Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs - MarketBeat
31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC - MarketBeat
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
William Blair Brokers Lift Earnings Estimates for Genmab A/S - MarketBeat
DAVENPORT & Co LLC Grows Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB - Defense World
QRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighHere's Why - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - sharewise.com
Why Genmab Stock Popped on Friday - The Globe and Mail
Leerink Partnrs Weighs in on Genmab A/S FY2027 Earnings - Defense World
Best Momentum Stock to Buy for October 3rd - sharewise.com
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright - Defense World
Genmab A/S Sponsored ADR $GMAB Stock Position Lowered by Signaturefd LLC - Defense World
New Strong Buy Stocks for October 3rd - Yahoo Finance
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):